1. Scrip
  2. >>New Products

Not Such A Sure Thing: FDA Knocks Back BioMarin’s Roctavian

Company’s Hemophilia A Gene Therapy Gets A CRL

 
• By Mandy Jackson

BioMarin’s confidence that its first-ever hemophilia gene therapy would be cleared by the US FDA was shaken by a complete response letter that the company claims changed the requirements for approval.

Hand holds a drop of blood. World Hemophilia Day. World Blood Donor Day.
Patients may have to wait two years or more for the first hemophilia A gene therapy • Source: Shutterstock

BioMarin Pharmaceutical Inc. insists that it did not know that the US Food and Drug Administration wanted to see longer-term data on its gene therapy Roctavian (valoctocogene roxaparvovec) for severe hemophilia A until it received a complete response letter from the agency.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.